Phathom Pharmaceuticals, Inc. Free Cash Flow per Share

Free Cash Flow per Share of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Free Cash Flow per Share growth rates and interactive chart. Free cash flow per share. Calculated as operating cash flow minus capital expenditures and divided by the weighted average number of shares outstanding. Free cash flow is the cash flow available to all the investors in a company, including common stockholders, preferred shareholders, and lenders. It is usually used in discounted cash flow models to determine a company's intrinsic value.


Highlights and Quick Summary

  • Free Cash Flow per Share for the quarter ending June 29, 2021 was -0.78 (a -43.63% decrease compared to previous quarter)
  • Year-over-year quarterly Free Cash Flow per Share increased by 23.73%
  • Annual Free Cash Flow per Share for 2020 was -2.12 (a -15.09% decrease from previous year)
  • Annual Free Cash Flow per Share for 2019 was -2.5 (a 5894.24% increase from previous year)
  • Twelve month Free Cash Flow per Share ending June 29, 2021 was -3.48 (a 16.46% increase compared to previous quarter)
  • Twelve month trailing Free Cash Flow per Share increased by 76.04% year-over-year
Trailing Free Cash Flow per Share for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
-3.48 -2.99 -2.07 -1.97
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Free Cash Flow per Share of Phathom Pharmaceuticals, Inc.

Most recent Free Cash Flow per Shareof PHAT including historical data for past 10 years.

Interactive Chart of Free Cash Flow per Share of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Free Cash Flow per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -0.78 -1.38
2020 -0.83 -0.63 -0.28 -0.37 -2.12
2019 -2.07 -0.97 -4.53 -0.12 -2.5
2018 0.0 -0.11 -0.04

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.